Metin, Mahmut Sami Atatürk Üniversitesi - Tıp Fakültesi - Deri ve Zührevi Hastalıkları Anabilim Dalı, Turkey , Kızılyel, Okan Atatürk Üniversitesi - Tıp Fakültesi - Deri ve Zührevi Hastalıkları Anabilim Dalı, Turkey , Elmas, Ömer Faruk Atatürk Üniversitesi - Tıp Fakültesi - Deri ve Zührevi Hastalıkları Anabilim Dalı, Turkey , Aktaş, Akın Atatürk Üniversitesi - Tıp Fakültesi - Deri ve Zührevi Hastalıkları Anabilim Dalı, Turkey

Erlotinib induced acneiform eruption: A case report

33368

Erlotinib is an epidermal growth factor inhibitor. It is used for refractory, local invasion or metastasized non-small cell lung cancer. Erlotinib doesn’t cause severe systemic side effects like cytotoxic drugs. But it causes toxic side effects in skin. Acneiform eruption is the most common side effects related to erlotinib using. It is thought that balance is disturbed between differentiation and maturation of keratinocytes, ecrine and sebaceous gland cells and hair follicle cells in etiology. Topical metronidazole, clindamycin, topical salicylic acid and tetracycline can be used in treatment. In case of severe acneiform eruption dose of erlotinib may be reduced or treatment of erlotinib may be delayed. Our case was 67 years old male presented with acneiform eruption on his face after erlotinib treatment for non-small cell lung cancer. We decide to report this case because early diagnosis and treatment of skin lesions related to erlotinib treatment is important for patient compliance with erlotinib treatment.

35

Acneiform eruption , erlotinib , non , small cell lung cancer

Cumhuriyet Medical Journal

37